Cardiff Oncology, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
CRDF$0.80+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(in thousands, except par value)
| December 31,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $17,470 | $51,470 |
| Short-term investments | 40,834 | 40,276 |
| Accounts receivable and unbilled receivable | 182 | 773 |
| Prepaid expenses and other current assets | 1,642 | 2,535 |
| Total current assets | 60,128 | 95,054 |
| Property and equipment, net | 578 | 898 |
| Operating lease right-of-use assets | 629 | 1,169 |
| Other assets | 549 | 69 |
| Total Assets | $61,884 | $97,190 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $8,087 | $4,821 |
| Accrued liabilities | 7,577 | 7,897 |
| Operating lease liabilities | 730 | 710 |
| Total current liabilities | 16,394 | 13,428 |
| Operating lease liabilities, net of current portion | 102 | 813 |
| Total Liabilities | 16,496 | 14,241 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 20,000 shares authorized; 277 designated as Series A Convertible Preferred Stock; 61 shares outstanding at December 31, 2025 and December 31, 2024 with liquidation preference of $1,117 and $1,092 at December 31, 2025 and December 31, 2024, respectively | — | — |
| Common stock, $0.0001 par value, 150,000 shares authorized; 68,305 and 66,524 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 7 | 7 |
| Additional paid-in capital | 475,361 | 467,087 |
| Accumulated other comprehensive gain | 50 | 34 |
| Accumulated deficit | (430,030) | (384,179) |
| Total stockholders’ equity | 45,388 | 82,949 |
| Total liabilities and stockholders’ equity | $61,884 | $97,190 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.